lasma disposables revenue was $59.8 million for the quarter, up 1%, and $172.2 million year to date, down 3%. Average weekly shipments of plasma disposables in the quarter were up 17% from the level of average daily shipments in Q4 of fiscal 10, which was the low point of the recent plasma downturn. Haemonetics expects its plasma business to return to high single digit growth in Q4 as we compare to a 14 week fiscal period in Q4 of fiscal 10, with full year Plasma revenue growth expected in a range of 0-2%.
Platelet disposables revenue was $41.1 million for the quarter, up 3%, and $ 117.1 million year to date, up 5%. The platelet business benefited from strong sales in our emerging markets. Haemonetics expects full year Platelet revenue growth of 1-3%.
Red cell disposables revenue was $11.7 million for the quarter, down 3%, and $34.3 million year to date, also down 3%. Revenue declined due to decreased demand for red cells as a result of declining surgical volumes. Haemonetics expects full year Red Cell disposable revenues within a range of a 3- 5% decrease.
Surgical disposables revenue was $17.1 million for the quarter, down 4%, and $49.5 million year to date, down 5%. The surgical business was also adversely impacted by trends in surgical volumes. Haemonetics expects full year surgical disposables revenues to decline approximately 5%.
OrthoPAT® orthopedic perioperative autotransfusion system disposables revenue was $9.2 million for the quarter, down 6%, and $26.5 million year to date down 2%. OrthoPAT sales to IMPACT accounts grew by 19% in the quarter and 30% year to date. Haemonetics expects full year OrthoPAT disposables revenues within a range of a 1- 5% decrease.
Diagnostic disposables revenue was $5.2 million for the quarter, up 21%, and $14.6 million year to date, up 23%. Revenues related to the TEG Thrombelastograph Hemostasis Analyzer b
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 Related biology technology :1
|SOURCE Haemonetics Corporation|
Copyright©2010 PR Newswire.
All rights reserved
. Haemonetics Receives Favorable Ruling in Patent Lawsuit against Competitive Technology2
. Neogen Reports 33% Increase in Net Income3
. Cardium Reports Excellagen Matrix Clinical Study Results Accepted for Publication by Peer-Reviewed Journal, and Updates Product Plans4
. New Topical Patent Research Reports Recently Published at MarketPublishers.com5
. YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT3876
. Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors7
. GeneLink Reports Third Quarter Results8
. Imagenetix, Inc. Reports Second Quarter 2011 Results9
. Transgenomic Reports Third Quarter Financial Results10
. Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results11
. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2011 Results; Teleconference and Webcast to be held on November 16, 2010